Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• The active drug (semaglutide) can be the same molecule whether it’s Wegovy (the branded, FDA‑approved product made by Novo Nordisk) or a compounded semaglutide product, but the real differences are in regulation, manufacturing quality, formulation, dosing consistency, safety testing, and clinical evidence. Wegovy has controlled manufacturing, proven clinical trial data for weight loss, and FDA labeling; compounded versions do not.

Key differences

1. Regulation and quality control

• Wegovy: manufactured under strict FDA oversight (Good Manufacturing Practices). Each lot is tested for purity, potency, sterility, stability and has lot tracing.
• Compounded semaglutide: made by compounding pharmacies that are not FDA‑approved drug manufacturers. Quality depends on the pharmacy’s procedures. Errors in dose, contamination, or impurity are possible if the pharmacy is not high quality.

1. Sterility and formulation

• Wegovy is supplied in a known sterile prefilled pen or vial with specific excipients and stability data.
• Compounded products may be supplied as prefilled syringes, vials, or cartridges made from bulk peptide powder and diluent. Sterility of the process and correct reconstitution are critical and can vary across pharmacies.

1. Dose accuracy and labeling

• Wegovy has validated delivery devices and clear titration schedules (approved doses up to 2.4 mg weekly for weight loss).
• Compounded products can vary in concentration and may be dosed or labeled inconsistently unless the pharmacy follows strict protocols and provides certificate of analysis.

1. Clinical evidence and safety

• Wegovy: large randomized clinical trials show efficacy and safety profile for weight loss, and monitoring recommendations are established.
• Compounded semaglutide: lacks the same trial evidence and post‑marketing safety data specific to that compounded formulation. Adverse effects may be similar to semaglutide, but formulation issues could cause additional risks (e.g., infections, injection reactions).

1. Legal, insurance and availability

• Wegovy is FDA‑approved and may be covered (partially) by some insurers, but it’s expensive and has had supply constraints.
• Compounded semaglutide is often less expensive out‑of‑pocket and may be used when Wegovy is unavailable, but insurers typically do not cover compounded weight‑loss products and there may be legal/regulatory limits in some states.

When people consider compounded semaglutide

• Main reasons: lower cost, easier access during Wegovy shortages, flexible dosing or syringe delivery.
• Main risks: variable potency, contamination, incorrect labeling, no guarantee of same bioavailability.

If you’re considering a compounded product — what to ask and look for

• Use a reputable, accredited pharmacy (look for Pharmacy Compounding Accreditation Board (PCAB) accreditation).
• Ask for Certificate of Analysis (CoA) for the raw peptide (identity/purity) and for final product sterility testing.
• Confirm the pharmacy follows USP <797> (sterile compounding) standards and has documented aseptic technique and batch records.
• Ask about storage, shelf life once compounded, trained staff, and how dose accuracy is verified.
• Ask your prescriber about monitoring and whether they’re comfortable prescribing a compounded product.
• Get clear written labeling, lot numbers, and instructions for handling/injection.

Practical recommendation

• If you can afford and access it, Wegovy (Novo Nordisk) is the safer, better‑studied choice for weight loss because of FDA approval, consistent manufacturing, and clinical trial evidence.
• If cost or access makes Wegovy impractical and you’re considering compounded semaglutide, only use a high-quality, PCAB‑accredited compounding pharmacy and discuss risks and monitoring with your clinician.

Alternatives to discuss with your clinician

• Ozempic (Novo Nordisk) — semaglutide for diabetes; sometimes used off‑label for weight loss at different dosing schedules.
• Zepbound (tirzepatide, Eli Lilly) — FDA‑approved for weight management (another GLP/GIP option).
• Mounjaro (tirzepatide) — approved for diabetes and used off‑label for weight loss; has strong weight‑loss effects in studies.

If you want, I can:

• Suggest specific questions to ask a compounding pharmacy,
• Help you find PCAB‑accredited compounding pharmacies in your area,
• Compare expected costs between Wegovy, Ozempic, and compounded options.